Skip to main content

Advertisement

SpringerLink
Log in

Comment on a meta-analysis evaluating the cardiac toxicity of lapatinib in patients with breast cancer and other HER2-positive cancers

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Choi HD, Chang MJ (2017) Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis. Breast Cancer Res Treat 166(3):927–936. https://doi.org/10.1007/s10549-017-4460-9

    Article  CAS  PubMed  Google Scholar 

  2. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Can Res 66(3):1630–1639. https://doi.org/10.1158/0008-5472.can-05-1182

    Article  CAS  Google Scholar 

  3. Ioannidis JP, Trikalinos TA (2007) An exploratory test for an excess of significant findings. Clin Trials (London, England) 4(3):245–253. https://doi.org/10.1177/1740774507079441

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast Surgery, The Affiliated Cancer Hospital of Guangxi Medical University, 71 He Di Road, Nanning, 530021, Guangxi, People’s Republic of China

    Qixing Tan & Changyuan Wei

Authors
  1. Qixing Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Changyuan Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Changyuan Wei.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This manuscript complies with the ethical rules applicable for this journal.

Research involving with human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tan, Q., Wei, C. Comment on a meta-analysis evaluating the cardiac toxicity of lapatinib in patients with breast cancer and other HER2-positive cancers. Breast Cancer Res Treat 168, 769–770 (2018). https://doi.org/10.1007/s10549-017-4648-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-017-4648-z

Search

Navigation